Journal of Rheumatic Diseases

Table. 4.

Resumption of DMARDs (n=9)* in the discontinuation group (n=13)

Cancer treatment Surgery only (n=3) Chemotherapy (n=6)
DMARDs (before cancer diagnosis → resumption) MTX+LEF → MTX MTX+SSZ+HCQ → MTX
MTX+SSZ → ETA MTX+LEF+HCQ → LEF+HCQ
MTX+ADA → same MTX+LEF+SSZ → LEF+HCQ
MTX+SSZ+TC → MTX
MTX+HCQ → same
MTX+HCQ → LEF+HCQ

DMARDs: disease modifying anti-rheumatic drugs, MTX: methotrexate, LEF: leflunomide, SSZ: sulfasalazine, HCQ: hydroxychloroquine, TC: tacrolimus, ETA: etanercept, ADA: adalimumab, IQR: interquartile range. *Time interval between discontinuation and resumption of DMARDs was median of 5.5 months (IQR 2.9, 18.3).

J Rheum Dis 2022;29:162~170 https://doi.org/10.4078/jrd.2022.29.3.162
© J Rheum Dis